Phosphate Binders and Targets Over Decades: Do We have it Right Now?

Area of Science:

• Nephrology
• Mineral Metabolism
• Cardiovascular Health

Background:

• Advanced renal disease impairs phosphate balance, leading to hyperphosphatemia.
• Hyperphosphatemia in chronic kidney disease (CKD) correlates with increased cardiovascular events and mortality.
• Existing phosphate-lowering therapies, like calcium-based binders, raise concerns about vascular mineralization.

Purpose of the Study:

• To review the history of phosphate targets and binders in CKD.
• To explore innovative phosphate-lowering therapies and nutritional approaches.
• To provide guidance on managing hyperphosphatemia in end-stage renal disease (ESRD).

Main Methods:

• Literature review of phosphate management in CKD.
• Analysis of current data on phosphate binders and novel therapies.
• Discussion of evolving guidelines from Kidney Disease: Improving Global Outcomes (KDIGO).

Main Results:

• No randomized controlled trials definitively prove hard outcome benefits from lowering serum phosphate to target levels in CKD or dialysis patients.
• Emerging data link calcium-based phosphate binders to increased vascular mineralization risks.
• Individualized treatment based on vascular mineralization risk factors is recommended.

Conclusions:

• Current hyperphosphatemia treatments in CKD require re-evaluation due to limited outcome data and safety concerns.
• Novel therapeutic strategies and nutritional interventions are crucial for managing phosphate balance.
• Personalized management of hyperphosphatemia in ESRD patients, considering vascular risks, is essential.